Biosimilars 2021 Year in Review
Fish & Richardson Trademark & Copyright Thoughts
JANUARY 11, 2022
For example, Amgen recently announced that it has Phase 3 studies under way to support interchangeability status for its adalimumab and ustekinumab biosimilars, Amjevita ™ and ABP 654, respectively. Neulasta ® (Amgen). Avsola ® (Amgen). Kanjinti ® (Amgen/ Allergan). Enbrel ® (Amgen). Rituxan ® (Roche/. Genentech).
52 
Let's personalize your content